Zimmer Biomet (NYSE:ZBH) Issues FY 2025 Earnings Guidance

Key Points

• Zimmer Biomet has updated its FY 2025 earnings guidance, projecting an EPS of 8.100-8.300 and revenue of $8.2 billion-$8.3 billion, surpassing analyst estimates.
• The company recently announced a quarterly dividend of $0.24 per share, amounting to an annualized dividend of $0.96 and a yield of 1.1%.
• Analysts have mixed ratings, with target prices ranging from $101.00 to $135.00, and Zimmer Biomet currently holds an average rating of "Hold" with a target price of $111.39.

Zimmer Biomet (NYSE:ZBH - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 8.100-8.300 for the period, compared to the consensus EPS estimate of 7.966. The company issued revenue guidance of $8.2 billion-$8.3 billion, compared to the consensus revenue estimate of $8.2 billion.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $91.21 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. The firm has a market cap of $18.05 billion, a P/E ratio of 20.18, a P/E/G ratio of 2.15 and a beta of 0.68. The firm's 50 day moving average price is $93.10 and its 200-day moving average price is $99.95. Zimmer Biomet has a one year low of $89.22 and a one year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.08. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. As a group, equities research analysts predict that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Analysts Set New Price Targets

ZBH has been the topic of several analyst reports. Royal Bank Of Canada reduced their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. JMP Securities lowered their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Roth Capital upgraded shares of Zimmer Biomet from a "neutral" rating to a "buy" rating and set a $135.00 price target on the stock in a research note on Tuesday, July 15th. Robert W. Baird decreased their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Truist Financial set a $101.00 target price on Zimmer Biomet in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and an average target price of $111.39.

Insider Buying and Selling

In related news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.39% of the company's stock.

Institutional Trading of Zimmer Biomet

An institutional investor recently bought a new position in Zimmer Biomet stock. Brighton Jones LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,936 shares of the medical equipment provider's stock, valued at approximately $204,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.